The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. This market-defining conference features keynotes on the state of the neurotech industry, cutting-edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.
7:30 am Conference Registration and Continental Breakfast
8:30 Welcome Keynote and State of Neurotech Industry 2017
Alison Fenney, Executive Director, Neurotechnology Industry Organization
Harry Tracy, President, NI Research
James Cavuoto, Editor & Publisher, Neurotech Reports
9:00 Investing in Neurotech Panel
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Josh Pinto, Vice President, CNS, Credit Suisse
Panelists: Andy Schwab, Managing Partner, 5AM Ventures
Joseph Sum, Analyst, EcoR1 Capital
Ilan Zipkin, Senior Investment Director, Takeda Venture Partners
Heath Lukatch, Partner and Managing Director, TPG Biotech
10:00 Coffee Break in the Exhibit Hall with Poster Viewing
10:40 Treatments for Alzheimer's and Cognitive Disorders
Globally, the population continues to age and the number of dementia patients keeps expanding. Ongoing efforts to develop disease modifying therapies have been plagued with failures. What new avenues are being pursued to address the growing global need? Will novel diagnostics allow us to initiate treatments earlier? What non-pharmacological options are in development?
Panelists: Casey Lynch, CEO, Cortexyme
Mark Gurney, CEO, Tetra Discovery Partners
Eyal Baror, CEO and President, Neuronix
11:40 Developments on the Horizon for Pain and Epilepsy
Ongoing research is revealing new pharmaceutical and device options to treat pain and epilepsy. Novel therapeutic modalities aim to decrease side effects and improve efficacy in treatment-resistant populations for epilepsy and neuropathic pain. What are the novel devices in this space? How are side effects being addressed?
Panelists: Alex Ni, CTO, Avertus
Alan Mock, Chief Commercial Officer, Algostim
12:40 pm Networking Luncheon
1:55 Internal and External Research & Development
Big pharma, big medtech and large biotech companies collaborate with smaller companies and academic institutions on a variety of projects. How can opportunities be spotted? What are current areas of interest? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations with academic groups, research institutes, and platform companies?
Moderator: Jay Kranzler, CEO, Regenovation
Panelists: Ryan Westphal, Director, Search and Evaluation, Neuroscience, Eli Lilly and Company
Thorsten Melcher, Senior Director, New Ventures, Johnson & Johnson Innovation
Anne Pianca, Director, R&D Neuromodulation, Boston Scientific
Rivka Kreitman, Senior Vice President & Head, Global Search and Evaluation, Teva Pharmaceuticals
2:55 Refreshment Break in the Exhibit Hall with Poster Viewing
3:35 Strategies in CNS Drug and Device Development
Intelligent trial design, fundraising, business development and product life cycle development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement.
Panelist: Tina Soulis, General Manager, Neuroscience Trials Australia
4:35 Emerging Company Showcase
Submissions to be accepted in February
5:35 Welcome Reception in the Exhibit Hall with Poster Viewing
6:30 Close of Day
7:30 Conference Registration and Continental Breakfast
8:30 Licensing and Acquisitions in Neurotech
Neurology is projected to be medtech's fastest-growing segment in the next five years. Pharma companies are adapting to the current environment with targeted deal-making. Overall all, big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? What are priority indications and requirements for licensing deals? Which companies are active in deal-making?
Moderator: Christine de los Reyes, Vice President, Strategic Planning & Business Development, Alopexx Enterprises
Panelists: Susan Lin, Vice President, New Ventures & Business Development, LivaNova
Jeff Calcagno, New Ventures, Johnson & Johnson Innovation
9:30 Parkinson's and Other Movement Disorders
Current treatments for movement disorders can improve functioning but suffer from side effects and "off" period especially as the disease progresses. What are the latest advances in movement disorders? What is in the pipeline to address side effects and other issues specific to this class? Can disease modifying treatments alter the course of disease? Can diagnostics improve treatment?
Moderator: John Reppas, Director, Public Policy, Neurotechnology Industry Organization
Panelist: Kyle Gano, Vice President, Business Development, Neurocrine Biosciences
10:30 Coffee Break in the Exhibit Hall with Poster Viewing
11:15 Next-Generation Psychiatry
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next-generation treatments? How will devices and diagnostics change the treatment landscape?
Moderator: Manuel Lopez Figueroa, Partner, Bay City Capital
Panelists: Yaron Daniely, President & CEO, Alcobra
Robert Linke, President & CEO, Embera NeuroTherapeutics
12:15 pm Networking Luncheon
1:30 Frontiers in Neurotechnology
In this session we will hear from companies on the cutting edge. Novel neurostimulation devices for a variety of indications, software solutions for neuropsychiatric markets, and new neurodiagnostic tools are on the brink of success. Which are the most exciting next-generation products and companies? How are they addressing unmet needs in neurotech?
Moderator: Imran Eba, Partner, Action Potential Venture Capital, GSK
Panelists: Corianna Lathan, CEO, Anthrotronix
Laura Tyler Perryman, CEO and Co-Founder, StimWave
Will Rosellini, CEO, Nexeon Medi
2:30 Neurotherapeutic Nutrition
Nutrition is at the core of novel approaches for disease prevention and treatments. What is neurotherapeutic nutrition? How can nutrition address CNS disorders? What companies are focusing on developing neurotherapeutic nutrition approaches? What hurdles will these companies face?
Moderator: Bram Goorden, Vice President, Global Head, Nestle Health Science
Panelists: John Andrews, CEO, Ketogen
Joan Fallon, CEO, Curemark
Jill C. Milne, CEO, Catabasis
3:30 Networking Refreshment Break
3:45 Targeting Orphan Diseases
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. Hear from companies developing treatments for ALS, lysosomal storage disorders, Huntington's, and more. What are the strategies to succeed in addressing a smaller market? Are R&D approaches different than for other indications?
Panelist: Tim Miller, CEO, Abeona Therapeutics
4:45 New Strategies in Multiple Sclerosis
Therapies directed at novel targets, more specific immune modulators and trophic factors are in development for multiple sclerosis. What are the promising treatments in development? How are indication-specific hurdles being addressed? What novel approaches are being pursued?
Panelists: Maurice Zauderer, CEO, Vaccinex
Marie Wesselhoft, President and Co-Founder, MSDx
5:45 Close of Conference